Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Lotem

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Nature Medicine|June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Cancer Cell|January 5, 2024
Interferon-stimulated neutrophils as a predictor of immunotherapy responseMadeleine Benguigui, Tim J Cooper, Prajakta Kalkar, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Cell Reports|May 26, 2021
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFRSoma Ghosh, Nishanth Belugali Nataraj, Ashish Noronha, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Frontiers in Immunology|March 15, 2024
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapyJair Bar, Raya Leibowitz, Niels Reinmuth, et al.
Neuro-Oncology|September 2, 2022
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cellsIoana Stejerean-Todoran, Phyllis A Gimotty, Andrea Watters, et al.
Cancer Discovery|September 14, 2018
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaShelly Kalaora, Yochai Wolf, Tali Feferman, et al.
The Journal of Clinical Investigation|October 15, 2021
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanomaAviyah Peri, Erez Greenstein, Michal Alon, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Nature Medicine|June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Cancer Cell|January 5, 2024
Interferon-stimulated neutrophils as a predictor of immunotherapy responseMadeleine Benguigui, Tim J Cooper, Prajakta Kalkar, et al.
The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.
Cell Reports|May 26, 2021
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFRSoma Ghosh, Nishanth Belugali Nataraj, Ashish Noronha, et al.
The Lancet. Oncology|July 27, 2019
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 studyCaroline Robert, Antoni Ribas, Jacob Schachter, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Frontiers in Immunology|March 15, 2024
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapyJair Bar, Raya Leibowitz, Niels Reinmuth, et al.
Neuro-Oncology|September 2, 2022
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cellsIoana Stejerean-Todoran, Phyllis A Gimotty, Andrea Watters, et al.
Cancer Discovery|September 14, 2018
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaShelly Kalaora, Yochai Wolf, Tali Feferman, et al.
The Journal of Clinical Investigation|October 15, 2021
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanomaAviyah Peri, Erez Greenstein, Michal Alon, et al.
Pageof 10